摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

trans-5-(2-fluorophenyl)-2-[3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexan]-4'-yl]imidazo[4,5-b]pyridine

中文名称
——
中文别名
——
英文名称
trans-5-(2-fluorophenyl)-2-[3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexan]-4'-yl]imidazo[4,5-b]pyridine
英文别名
4-[5-(2-fluorophenyl)-1H-imidazo[4,5-b]pyridin-2-yl]spiro[cyclohexane-1,3'-furo[3,4-c]pyridine]-1'-one
trans-5-(2-fluorophenyl)-2-[3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexan]-4'-yl]imidazo[4,5-b]pyridine化学式
CAS
——
化学式
C24H19FN4O2
mdl
——
分子量
414.439
InChiKey
XBZQPGYRLGSWLB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    31
  • 可旋转键数:
    2
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    80.8
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • Novel benzimidazole derivatives
    申请人:Otake Norikazu
    公开号:US20060205750A1
    公开(公告)日:2006-09-14
    The present invention relates to a compound of the formula (I): (wherein A, B , C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO 2 R 4 )—, —N(COR 5 )— or —CO—; Y is —C(R 6 )(R 7 )—, —O— or —N(R 8 )—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.
    本发明涉及一种式(I)的化合物:其中A、B、C和D分别独立表示氮或可选取代的甲烷基;E表示氮、甲烷基或羟基取代的甲烷基;n为0或1;T、U、V和W分别独立表示氮或可选取代的甲烷基;X为—N(SO2R4)—、—N(COR5)—或—CO—;Y为—C(R6)(R7)—、—O—或—N(R8)—,但当化合物(I)中E为氮,n为0,X为—CO—,Y为—O—时,该化合物被排除在外。此外,该化合物及其类似物可用作治疗与NPY相关的各种疾病的药物,例如心血管疾病如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛、动脉硬化等;中枢神经系统疾病如贪食症、抑郁症、焦虑症、癫痫、痴呆、疼痛、酗酒、戒断症状、生物钟紊乱、精神分裂症、记忆力减退、睡眠障碍、认知障碍等;代谢性疾病如肥胖症、糖尿病、激素异常、高胆固醇血症、高脂血症、痛风、脂肪肝等;生殖系统疾病如不孕症、早产、性功能障碍等;胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等;例如动脉粥样硬化、性腺功能减退、高雄激素血症、多囊卵巢综合症(皮克威克综合症)、多毛症、胃肠道运动障碍、肥胖相关的胃食管反流、肥胖低通气综合症、睡眠呼吸暂停、炎症、血管系统全身性炎症、骨关节炎、胰岛素抵抗、支气管收缩、酒精偏好、代谢综合症、阿尔茨海默病、心脏肥大、左心室肥大、高三酰甘油血症、低高密度脂蛋白胆固醇、心血管疾病如冠心病、脑血管疾病、中风、周围血管疾病、猝死、胆囊疾病、癌症(乳腺、子宫内膜、结肠)、呼吸困难、高尿酸血症、生育能力下降、腰痛或麻醉风险增加等。
  • NOVEL BENZIMIDAZOLE DERIVATIVES
    申请人:OTAKE NORIKAZU
    公开号:US20100048600A1
    公开(公告)日:2010-02-25
    The present invention relates to a compound of the formula (I): (wherein A, B , C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO 2 R 4 )—, —N(COR 5 )— or —CO—; Y is —C(R 6 )(R 7 )—, —O— or —N(R 8 )—, provided that the compound (I) when E is nitrogen, n is 0, X is —CO—, and Y is —O— is excluded) and the like, which are useful as an agent for the treatment of various diseases related to NPY, for example cardiovascular disorders such as angina, acute or congestive heart failure, myocardial infarction, hypertension, nephropathy, electrolyte abnormality, vasospasm, arteriosclerosis, etc., central nervous system disorders such as bulimia, depression, anxiety, seizure, epilepsy, dementia, pain, alcoholism, drug withdrawal, circadian rhythm disorders, schizophrenia, memory impairment, sleep disorders, cognitive impairment, etc., metabolic diseases such as obesity, diabetes, hormone abnormality, hypercholesterolemia, hyperlipidemia, gout, fatty liver, etc., genital or reproductive disorders such as infertility, preterm labor, sexual dysfunction, etc., gastro-intestinal disorders, respiratory disorder, inflammatory diseases or glaucoma, and the like, also for example, atherosclerosis, hypogonadism, hyperandrogenism, polycystic ovary syndrome (Pickwickian syndrome), hirsutism, gastro-intestinal motility disorder, obesity-related gastro-esophageal reflux, obesity hypoventilation, sleep apnea, inflammation, systemic inflammation of the vasculature, osteoarthritis, insulin resistance, bronchoconstriction, alcohol preference, metabolic syndrome, Alzheimer's disease, cardiac hypertrophy, left ventricular hypertrophy, hypertriglyceridemia, low HDL cholesterol, cardiovascular disorders such as coronary heart disease (CHD), cerebrovascular disease, stroke, peripheral vascular disease, sudden death, gallbladder diseases, cancer (breast, endometrial, colon), breathlessness, hyperuricemia, impaired fertility, low back pain, or increased anesthetic risk, and the like.
    本发明涉及一种式(I)的化合物:其中A、B、C和D独立地表示氮或可选取代的亚甲基;E表示氮、亚甲基或羟基取代的亚甲基;n为0或1;T、U、V和W独立地表示氮或可选取代的亚甲基;X为-N(SO2R4)-、-N(COR5)-或-CO-;Y为-C(R6)(R7)-、-O-或-N(R8)-,但当E为氮,n为0,X为-CO-,且Y为-O-时,化合物(I)被排除。此类化合物可用作治疗与NPY相关的各种疾病的药物,例如心血管疾病(如心绞痛、急性或充血性心力衰竭、心肌梗死、高血压、肾病、电解质异常、血管痉挛、动脉硬化等)、中枢神经系统疾病(如暴食症、抑郁症、焦虑症、癫痫、老年痴呆、疼痛、酗酒、戒毒、昼夜节律紊乱、精神分裂症、记忆障碍、睡眠障碍、认知障碍等)、代谢性疾病(如肥胖症、糖尿病、激素异常、高胆固醇血症、高脂血症、痛风、脂肪肝等)、生殖系统或生殖障碍(如不孕症、早产、性功能障碍等)、胃肠道疾病、呼吸系统疾病、炎症性疾病或青光眼等,例如动脉粥样硬化、性腺功能减退、高雄激素症、多囊卵巢综合征(匹克威克综合征)、多毛症、胃肠道运动障碍、肥胖相关胃食管反流、肥胖低通气综合征、睡眠呼吸暂停、炎症、血管系统全身性炎症、骨关节炎、胰岛素抵抗、支气管收缩、酒精偏好、代谢综合征、阿尔茨海默病、心脏肥大、左心室肥大、高三酰甘油血症、低高密度脂蛋白胆固醇、心血管疾病如冠心病、脑血管疾病、中风、外周血管疾病、猝死、胆囊疾病、癌症(乳腺、子宫内膜、结肠)、气短、高尿酸血症、生育能力受损、腰痛或麻醉风险增加等。
  • US7105526B2
    申请人:——
    公开号:US7105526B2
    公开(公告)日:2006-09-12
  • US7687514B2
    申请人:——
    公开号:US7687514B2
    公开(公告)日:2010-03-30
  • US7803807B2
    申请人:——
    公开号:US7803807B2
    公开(公告)日:2010-09-28
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-